What are the long-term risks of testosterone therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Long-Term Testosterone Therapy Carries Specific Risks That Require Monitoring, But Most Are Manageable

Long-term testosterone therapy is generally safe when properly monitored, with the most significant risks being erythrocytosis (elevated red blood cells) and potential prostate concerns, while recent high-quality evidence shows no increased cardiovascular or prostate cancer risk in appropriately selected patients 1, 2.

Key Risks by Clinical Significance

High-Priority Risks Requiring Active Monitoring

Erythrocytosis (Polycythemia)

  • Most common clinically significant risk, occurring in 3-18% with transdermal formulations and up to 44% with intramuscular injections 3
  • Requires regular hemoglobin/hematocrit monitoring throughout treatment 4
  • Can increase thrombotic risk if unrecognized
  • Management: Dose reduction or temporary discontinuation if hematocrit exceeds safe thresholds

Prostate Monitoring Requirements

  • Prostate cancer risk remains controversial with "unknown level of risk" requiring long-term monitoring 3
  • FDA labeling warns of increased risk of prostatic hypertrophy and carcinoma in geriatric patients, though conclusive evidence is lacking 4
  • Recent meta-analysis of 41 RCTs found no statistically significant increase in prostate cancer events (OR 0.88; 95% CI: 0.52-1.51) 2
  • Contraindicated in men with existing prostate cancer 4

Cardiovascular Safety: Recent Evidence vs. Historical Concerns

The cardiovascular risk profile has evolved significantly with new data:

Reassuring Recent Evidence:

  • The TRAVERSE trial (2024)—the largest and highest-quality study—found no increase in major adverse cardiac events in 5,246 men followed for mean 27.1 months 1
  • 2026 meta-analysis of 41 RCTs showed no significant MACE increase (OR 0.83; 95% CI: 0.52-1.32) 2
  • Historical guideline data suggested neutral or possibly beneficial cardiovascular effects 3

Concerning Contradictory Evidence:

  • 2025 real-world cohort study found 55% increased MACE risk with long-term use (HR 1.55; 95% CI: 1.19-2.01) 5
  • 2019 UK study showed increased risk in first 6 months to 2 years of use (HR 1.35; 95% CI: 1.01-1.79), particularly in men aged 45-59 6
  • One 2004 veterans study found increased composite endpoint of mortality/MI/stroke (HR 1.29) 7

Clinical Interpretation: The highest-quality randomized evidence (TRAVERSE) should guide practice, showing safety in appropriately selected patients. However, highest risk appears in the first 2 years of therapy and in younger men (45-59 years), requiring closer monitoring during this period 6.

Moderate-Risk Side Effects

Testicular Atrophy and Infertility

  • Common, especially in young men 3
  • Usually reversible with cessation 3
  • Critical counseling point for men of reproductive age

Sleep Apnea

  • Infrequent but documented risk 3
  • One observational study found increased risk 7

Dermatologic Effects

  • Acne most frequent (0.6-9.1% depending on formulation) 8
  • Skin reactions highly variable by delivery method: patches up to 66%, gels 5%, injections rare 3, 8
  • Can significantly impact adherence despite being "non-severe" 8

Low-Risk or Rarely Clinically Significant

  • Fluid retention: rarely clinically significant 3
  • Benign prostatic hyperplasia: rarely clinically significant 3
  • Gynecomastia: rare, usually reversible 3
  • Lipid alterations: most studies show no change with physiologic doses 3

Critical Monitoring Algorithm

Baseline Requirements:

  • Two fasting testosterone levels <10.4 nmol/L (300 ng/dL) with symptoms 1, 9
  • Screen for cardiovascular disease, prostate cancer, elevated PSA 1
  • Baseline hemoglobin/hematocrit 4

Ongoing Monitoring:

  • Hemoglobin/hematocrit: periodically throughout treatment 4
  • Symptom response assessment 9
  • Prostate monitoring: long-term surveillance required 3
  • Intensify cardiovascular monitoring in first 2 years, especially in men under 60 6

Common Pitfalls to Avoid

  1. Using testosterone in men without documented hypogonadism (symptoms + low testosterone on two occasions)
  2. Failing to monitor hematocrit, leading to unrecognized erythrocytosis
  3. Prescribing to men with active prostate cancer or recent cardiovascular events—these are contraindications
  4. Inadequate counseling of young men about fertility effects
  5. Assuming all formulations have equal risk profiles—injectable testosterone has highest erythrocytosis risk (up to 44%) 3

Formulation-Specific Considerations

Injectable testosterone carries highest erythrocytosis risk but lowest dermatologic reactions. Transdermal patches have highest skin reaction rates (up to 66%) but lower systemic risks. Oral formulations have lowest acne rates but carry hepatotoxicity concerns 3, 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.